Bank of New York Mellon’s CorMedix CRMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.11M | Buy |
395,907
+29,394
| +8% | +$232K | ﹤0.01% | 2707 |
|
|
2026
Q1 | $2.49M | Sell |
366,513
-10,394
| -3% | -$76.8K | ﹤0.01% | 2701 |
|
|
2025
Q4 | $4.38M | Buy |
376,907
+118,122
| +46% | +$1.31M | ﹤0.01% | 2397 |
|
|
2025
Q3 | $3.01M | Buy |
258,785
+47,845
| +23% | +$578K | ﹤0.01% | 2596 |
|
|
2025
Q2 | $2.6M | Buy |
210,940
+67,702
| +47% | +$747K | ﹤0.01% | 2620 |
|
|
2025
Q1 | $882K | Buy |
143,238
+13,543
| +10% | +$140K | ﹤0.01% | 3141 |
|
|
2024
Q4 | $1.05M | Buy |
129,695
+9,782
| +8% | +$97.7K | ﹤0.01% | 3135 |
|
|
2024
Q3 | $969K | Sell |
119,913
-38,988
| -25% | -$211K | ﹤0.01% | 3151 |
|
|
2024
Q2 | $688K | Buy |
158,901
+25,677
| +19% | +$130K | ﹤0.01% | 3387 |
|
|
2024
Q1 | $565K | Sell |
133,224
-30,667
| -19% | -$106K | ﹤0.01% | 3446 |
|
|
2023
Q4 | $616K | Buy |
163,891
+12,325
| +8% | +$42.4K | ﹤0.01% | 3433 |
|
|
2023
Q3 | $561K | Buy |
151,566
+21,185
| +16% | +$84.2K | ﹤0.01% | 3484 |
|
|
2023
Q2 | $517K | Buy |
130,381
+106,365
| +443% | +$526K | ﹤0.01% | 3572 |
|
|
2023
Q1 | $99.4K | Hold |
24,016
| – | – | ﹤0.01% | 4079 |
|
|
2022
Q4 | $101K | Sell |
24,016
-62
| -0.3% | -$219 | ﹤0.01% | 4112 |
|
|
2022
Q3 | $68K | Hold |
24,078
| – | – | ﹤0.01% | 4270 |
|
|
2022
Q2 | $97K | Sell |
24,078
-101,805
| -81% | -$378K | ﹤0.01% | 4227 |
|
|
2022
Q1 | $690K | Buy |
125,883
+1,252
| +1% | +$5.73K | ﹤0.01% | 3521 |
|
|
2021
Q4 | $567K | Buy |
124,631
+1,714
| +1% | +$8.51K | ﹤0.01% | 3726 |
|
|
2021
Q3 | $571K | Buy |
122,917
+8,206
| +7% | +$47.8K | ﹤0.01% | 3735 |
|
|
2021
Q2 | $786K | Buy |
114,711
+19,845
| +21% | +$158K | ﹤0.01% | 3557 |
|
|
2021
Q1 | $947K | Sell |
94,866
-4,272
| -4% | -$45K | ﹤0.01% | 3364 |
|
|
2020
Q4 | $737K | Buy |
99,138
+7,871
| +9% | +$53.5K | ﹤0.01% | 3423 |
|
|
2020
Q3 | $550K | Sell |
91,267
-926
| -1% | -$4.65K | ﹤0.01% | 3445 |
|
|
2020
Q2 | $582K | Buy |
92,193
+2,306
| +3% | +$10.7K | ﹤0.01% | 3403 |
|
|
2020
Q1 | $322K | Buy |
89,887
+5,446
| +6% | +$30.8K | ﹤0.01% | 3572 |
|
|
2019
Q4 | $615K | Buy |
84,441
+6,352
| +8% | +$38.8K | ﹤0.01% | 3477 |
|
|
2019
Q3 | $498K | Sell |
78,089
-142
| -0.2% | -$1.19K | ﹤0.01% | 3538 |
|
|
2019
Q2 | $701K | Buy |
78,231
+50,152
| +179% | +$394K | ﹤0.01% | 3429 |
|
|
2019
Q1 | $265K | Sell |
28,079
-2,059
| -7% | -$18.6K | ﹤0.01% | 3788 |
|
|
2018
Q4 | $194K | Buy |
30,138
+22,606
| +300% | +$151K | ﹤0.01% | 3861 |
|
|
2018
Q3 | $36K | Hold |
7,532
| – | – | ﹤0.01% | 4162 |
|
|
2018
Q2 | $9K | Sell |
7,532
-1,532
| -17% | -$1.77K | ﹤0.01% | 4197 |
|
|
2018
Q1 | $8K | Sell |
9,064
-3,457
| -28% | -$6.9K | ﹤0.01% | 4295 |
|
|
2017
Q4 | $32K | Buy |
12,521
+4,989
| +66% | +$14.3K | ﹤0.01% | 4258 |
|
|
2017
Q3 | $20K | Hold |
7,532
| – | – | ﹤0.01% | 4214 |
|
|
2017
Q2 | $16K | Sell |
7,532
-1,188
| -14% | -$4.06K | ﹤0.01% | 4245 |
|
|
2017
Q1 | $71K | Buy |
8,720
+1,185
| +16% | +$11.3K | ﹤0.01% | 4091 |
|
|
2016
Q4 | $58K | Sell |
7,535
-493
| -6% | -$4.99K | ﹤0.01% | 4114 |
|
|
2016
Q3 | $101K | Sell |
8,028
-1,429
| -15% | -$13.4K | ﹤0.01% | 4040 |
|
|
2016
Q2 | $94K | Sell |
9,457
-13,810
| -59% | -$210K | ﹤0.01% | 4070 |
|
|
2016
Q1 | $308K | Buy |
23,267
+363
| +2% | +$3.52K | ﹤0.01% | 3636 |
|
|
2015
Q4 | $232K | Buy |
22,904
+917
| +4% | +$10.6K | ﹤0.01% | 3824 |
|
|
2015
Q3 | $219K | Sell |
21,987
-1,568
| -7% | -$24.2K | ﹤0.01% | 3874 |
|
|
2015
Q2 | $456K | Buy |
23,555
+17,833
| +312% | +$612K | ﹤0.01% | 3670 |
|
|
2015
Q1 | $282K | Buy |
+5,722
| New | +$136K | ﹤0.01% | 3799 |
|
Other funds holding CRMD
HWAM
PIP
PAG
Bank of New York Mellon's CRMD Position: Q2 2026 in Review
Bank of New York Mellon increased its CorMedix (CRMD) stake by 8% in Q2 2026, buying an estimated $232K and bringing the position to 395,907 shares worth $3.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2707.
Bank of New York Mellon first reported a position in CRMD in Q1 2015 and has held it in 46 quarters since. The position peaked at $4.38M in Q4 2025. 66 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.
- Bank of New York Mellon held 395,907 shares of CorMedix worth $3.11M as of Q2 2026.
- Bank of New York Mellon bought 29,394 CorMedix shares in Q2 2026, an estimated $232K.
- CorMedix made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2707 holding.
- Bank of New York Mellon first reported a position in CorMedix in Q1 2015 and has held it in 46 quarters since.
- Bank of New York Mellon's CorMedix position peaked at $4.38M in Q4 2025.
- 66 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.